Healthcare

Medline raises 6.26 billion in the biggest IPO of the year

The company, participated by Blackstone, Carlyle Group and Hellman & Friedman, placed 216 million shares at $29 for a valuation of $39 billion

by Monica D'Ascenzo

3' min read

Translated by AI
Versione italiana

3' min read

Translated by AI
Versione italiana

The biggest IPO of the year came in December and it was Medline. The company, participated by Blackstone, Carlyle Group and Hellman & Friedman, raised $6.26 billion, increasing the size of the deal and setting the share price near the top of the indicated range. A total of 216 million shares were placed, against the initial offering of 179 million, at $29 each in the range of $26 to $30. The implied valuation is about $39 billion, based on the number of shares indicated in the documents filed with the US Securities and Exchange Commission (SEC).

The deal surpasses the previous largest listing of the year, the $5.26 billion listing in Hong Kong of Chinese battery maker Contemporary Amperex Technology Co, and also Venture Global's $1.75 billion offering in January, which had so far been the largest in the US in 2025.

Loading...

Transaction details

The deal is also the largest IPO of a predominantly private equity-controlled company, surpassing the $5.1 billion listing of Lineage Inc. last year, backed by Bay Grove Capital. And Wall Street is looking to private equity funds as a potential driver for more new listings next year, by bringing a significant portion of their portfolios to the stock market.

The three private equity firms had taken over the company, which manufactures and distributes medical supplies such as gloves, gowns and examination couches used by hospitals and doctors, in a $34 billion deal in 2021 to acquire a controlling stake in the group, in one of the largest leveraged buyouts ever. It is now worth $5 billion more than four years ago.

Medline had confidentially filed its listing documents with the US SEC late last year, but tariffs-related uncertainty delayed plans to go public in the first half of 2025. The US government shutdown in the second half of the year also further complicated preparations, with the public filing of the documents taking place during the dispute, which ended on 12 November.

In the deal, the company also obtained commitments of up to USD 2.35 billion from cornerstone investors, including Baillie Gifford, Capital Group, Morgan Stanley's Counterpoint Global, Durable Capital Partners, Singapore's sovereign wealth fund GIC Pte, Janus Henderson Investors, Viking Global Investors and WCM Investment Management.

Goldman Sachs Group Inc, Morgan Stanley, Bank of America Corp. and JPMorgan Chase & Co. led the placement, joined by 21 joint bookrunners and 21 co-managers. Medline plans to begin trading on Wednesday on the Nasdaq Global Select Market under the symbol MDLN.

The Medline Story

Medline was founded in 1966 by brothers Jon and Jim Mills. The Mills family, which remained the largest individual shareholder even after the buyout, will hold 17.8% of the voting rights after the IPO. Blackstone, Carlyle and Hellman & Friedman will each have 18% of the voting rights. In detail, the members of the Mills family and related entities had indicated their intention to purchase up to $250 million worth of shares as part of the IPO, according to the documents.

After the private equity buyout, the company embarked on a management transition under the leadership of Jim Boyle, a 28-year veteran of the group and the first non-Mills family CEO. In 2024, Medline acquired Ecolab's surgical solutions business for approximately $905 million and has invested $1.6 billion in capital expenditures in its distribution network over the past five years.

Medline offers a portfolio of about 335,000 medical-surgical products and has a supply chain that enables next-day delivery to 95% of its US customers. The group employs over 43,000 people worldwide.

In the nine months ended 27 September, the company posteda net profit of USD 977 million on revenues of USD 20.6 billion, which compares with a net profit of USD 911 million and revenues of USD 18.7 billion in the same period last year.

The 2025 US IPOs

IPOs in the US have raised over $46 billion this year, excluding special purpose entities (SPACs), according to Bloomberg data. Even including Medline, the total is expected to remain slightly below the annual average of nearly $50 billion recorded in the decade prior to the pandemic.With $6.26 billion raised, Medline is only the fifth listed company in the US to exceed $5 billion in an IPO in the past decade, according to Bloomberg data. The other four are Uber Technologies, Lineage, Rivian Automotive and Arm Holdings.

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti